Posts tagged financing
Microbix appoints Cameron Groome as President, CEO

Microbix Biosystems (TSX:MBX) has appointed Cameron Groome as its president and CEO, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to ensure a smooth leadership transition.

Read More
AmorChem spins out CD36 technology into Mperia Therapeutics

Closely-held AmorChem has spun out Mperia Therapeutics, a start-up company focusing on a novel immunotherapy approach based on CD36 cell receptor drug-ligands.

All rights to the CD36 technology initially held by AmorChem have been transferred to Mperia, with a first Series A investment of $1-million. The capital injection will allow Mperia to pursue early-stage development of lead candidates for the treatment of dry age-related macular degeneration (AMD), a leading cause of blindness in seniors.

Read More
GeneNews resolves TSX, OSC issues

GeneNews (TSX:GEN), by raising additional financings via a series of transactions over the past few weeks, and filing its full year 2015 and 2016 first quarter results, has successfully resolved both the Toronto Stock Exchange continued listing review and the management cease trade order granted by the Ontario Securities Commission in March.

“The last six-to-12 months have been a challenging time for both the company and its shareholders,” executive chairman, James Howard-Tripp, said in a statement.

Read More
Vital Connect closes new financing round

Closely-held Vital Connect, a leader in medical-grade wearable biosensor systems, has closed a term loan facility of $17.5-million with Perceptive Advisors, of which $10-million was funded at the initial closing today. Armentum Partners acted as financial advisor to Vital Connect in conjunction with this financing.

The company also recently extended its Series B round in order to raise an additional $7.8-million of equity capital, bringing the total raised to date in the Series B round to $22.1-million.

Read More
Roth adjusts DelMar Pharma price target to $12

Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday.

Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a senior exchange, either NASDAQ or NYSE-MKT, shortly.

Read More
GeneNews closes note financing with Alumina

GeneNews (TSX:GEN) has executed a definitive financing agreement with Alumina Partners for a second tranche of a non-brokered private placement.

Under the accord, GeneNews will draw down on $10-million in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period. The initial draw will be limited to $200,000 within the first 120 days. The 12% notes will have a term of one year.

Read More
GeneNews provides financing update

GeneNews (TSX:GEN) has closed the first tranche of a private placement, consisting of the issuance of approximately 5.6 million common shares at a price of 10 cents each, for gross proceeds of approximately $560,000, to be used for working capital.

The company also has executed a term sheet with Alumina Partners for a second tranche, allowing GeneNews to draw down on $10-million (US) in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period.

Read More